Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies (Q37000638)

17 August 2017

1 reference

title

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies (English)

1 reference

17 August 2017

0 references

0 references

Steven J O'Day

1

1 reference

17 August 2017

Omid Hamid

series ordinal

2

1 reference

17 August 2017

Walter J Urba

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

110

1 reference

17 August 2017

12

1 reference

17 August 2017

2614-2627

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Dendritic cells: immune saviors or Achilles' heel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Interactions between MHC molecules and co-receptors of the TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

The therapeutic potential of 4-1BB (CD137) in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

CTLA-4 and its role in autoimmune thyroid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

Cancer; a biological approach. I. The processes of control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

T-cell costimulation--biology, therapeutic potential, and challenges

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

CD28/B7 costimulation: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

Checkpoint blockade in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23086

7 January 2021

Identifiers

DOI

10.1002/CNCR.23086

1 reference

17 August 2017

1 reference